Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hor… Read more
Terns Pharmaceuticals Inc (TERN) - Net Assets
Latest net assets as of September 2025: $284.07 Million USD
Based on the latest financial reports, Terns Pharmaceuticals Inc (TERN) has net assets worth $284.07 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($301.65 Million) and total liabilities ($17.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $284.07 Million |
| % of Total Assets | 94.17% |
| Annual Growth Rate | 29.82% |
| 5-Year Change | 404.24% |
| 10-Year Change | N/A |
| Growth Volatility | 111.02 |
Terns Pharmaceuticals Inc - Net Assets Trend (2018–2024)
This chart illustrates how Terns Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Terns Pharmaceuticals Inc (2018–2024)
The table below shows the annual net assets of Terns Pharmaceuticals Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $345.87 Million | +35.44% |
| 2023-12-31 | $255.37 Million | -7.79% |
| 2022-12-31 | $276.94 Million | +72.76% |
| 2021-12-31 | $160.30 Million | +133.71% |
| 2020-12-31 | $68.59 Million | +274.33% |
| 2019-12-31 | $18.32 Million | -74.63% |
| 2018-12-31 | $72.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Terns Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39823000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.00% |
| Other Comprehensive Income | $-279.00K | -0.08% |
| Other Components | $767.62 Million | 221.94% |
| Total Equity | $345.87 Million | 100.00% |
Terns Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Terns Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sega Sammy Holdings Inc
PINK:SGAMF
|
$3.09 Billion |
|
Nissin Foods Holdings Co.Ltd
F:NF2
|
$3.09 Billion |
|
PENNON GROUP NEW LS-6105
F:3PN
|
$3.09 Billion |
|
TransAlta Corp
NYSE:TAC
|
$3.09 Billion |
|
NMDC Limited
NSE:NMDC
|
$3.09 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
$3.08 Billion |
|
Siemens Limited
NSE:SIEMENS
|
$3.08 Billion |
|
Dabur India Limited
NSE:DABUR
|
$3.08 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Terns Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 255,367,000 to 345,870,000, a change of 90,503,000 (35.4%).
- Net loss of 88,853,000 reduced equity.
- New share issuances of 162,312,000 increased equity.
- Other comprehensive income decreased equity by 260,000.
- Other factors increased equity by 17,304,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-88.85 Million | -25.69% |
| Share Issuances | $162.31 Million | +46.93% |
| Other Comprehensive Income | $-260.00K | -0.08% |
| Other Changes | $17.30 Million | +5.0% |
| Total Change | $- | 35.44% |
Book Value vs Market Value Analysis
This analysis compares Terns Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.68x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 15.42x to 10.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $3.01 | $46.47 | x |
| 2019-12-31 | $0.17 | $46.47 | x |
| 2020-12-31 | $2.73 | $46.47 | x |
| 2021-12-31 | $6.34 | $46.47 | x |
| 2022-12-31 | $7.69 | $46.47 | x |
| 2023-12-31 | $3.58 | $46.47 | x |
| 2024-12-31 | $4.35 | $46.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Terns Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-25.69%) is above the historical average (-259.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -24.52% | 0.00% | 0.00x | 1.23x | $-24.93 Million |
| 2019 | -1635.82% | 0.00% | 0.00x | 5.68x | $-69.24 Million |
| 2020 | -42.79% | 0.00% | 0.00x | 1.35x | $-36.21 Million |
| 2021 | -31.29% | -5015.80% | 0.01x | 1.05x | $-66.19 Million |
| 2022 | -21.79% | 0.00% | 0.00x | 1.04x | $-88.04 Million |
| 2023 | -35.33% | 0.00% | 0.00x | 1.05x | $-115.75 Million |
| 2024 | -25.69% | 0.00% | 0.00x | 1.05x | $-123.44 Million |
Industry Comparison
This section compares Terns Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Terns Pharmaceuticals Inc (TERN) | $284.07 Million | -24.52% | 0.06x | $3.09 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |